Navigation Links
Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
Date:4/16/2008

, the dose-ranging study of our H5N1 pandemic flu vaccine is enrolling as projected based on the favorable interim safety and immunogenicity analyses conducted last December. We plan to have the final doses selected for late stage development for both the pandemic and seasonal flu vaccine programs by the second half of this year," Dr. Heaton said.

"These results support on-going development of our trivalent seasonal influenza vaccine and keeps us on track to commence human trials of this vaccine candidate in the third quarter of 2008," said Rahul Singhvi, President and Chief Executive Officer of Novavax, Inc. "We will have two vaccines in Phase II development by the second half of this year."

The company is also preparing its seasonal VLP vaccine candidate for head-to-head human studies against a marketed flu vaccine beginning in the fourth quarter of 2008. Virus-like particles have been created for each of the three new flu vaccine strains recommended by the Centers for Disease Control and Prevention ("CDC") for the upcoming 2008-2009 season. Historically, it is not common for CDC to recommend changing all three strains of the seasonal influenza vaccine, however, even with this recommendation, Novavax has been able to construct the corresponding VLPs within six weeks of the announcement. We believe that the ability of Novavax to respond quickly to emerging flu strains using its proprietary recombinant VLP technology could significantly differentiate Novavax from other flu vaccine companies.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based highly potent, recombinant vaccines utilizing a new, efficient manufacturing solution.

Forward-Looking Statements

Statements herein relating to future financial or business performance,
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
2. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
3. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
4. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
5. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
6. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
7. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
8. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
9. NOLabs AB Reports Success in Fight Against Bacteria Causing Urinary Tract Infection
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...
(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...
(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...
Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3Exposure to lead tobacco smoke raises risk of ADHD 10856 1Exposure to lead tobacco smoke raises risk of ADHD 10856 2Measuring and modeling blood flow in malaria 61892 1Measuring and modeling blood flow in malaria 61892 2
... Phase III pivotal study of LY2062430 in ... ... and Company (NYSE:,LLY) today announced interim results of its Phase II study ... moderate Alzheimer,s disease. In this study, intravenously,administered LY2062430 bound to the amyloid ...
... tablets) Now the Only Alzheimer,s Disease Drug ... Studied in Two ... and Pfizer Inc (NYSE:,PFE) announced today results from a new ... (AD) experienced,significant improvement in cognition compared to baseline after 12 ...
Other Medicine Technology:Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease 2Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease 3Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease 4Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease 5Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease 6First Ever Study on Alzheimer's Disease Treatment in Hispanics Presented at Major Medical Meeting 2First Ever Study on Alzheimer's Disease Treatment in Hispanics Presented at Major Medical Meeting 3First Ever Study on Alzheimer's Disease Treatment in Hispanics Presented at Major Medical Meeting 4First Ever Study on Alzheimer's Disease Treatment in Hispanics Presented at Major Medical Meeting 5
(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...
(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...
(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...
(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...
(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...
Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:New Hampshire Kids 'Kick Butts' on March 24 2Health News:New Hampshire Kids 'Kick Butts' on March 24 3Health News:New Hampshire Kids 'Kick Butts' on March 24 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Residency match results not encouraging for adults needing primary care 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3
... plants, has been pin pointed in humans as being responsible for ... of developing an inherited form of the diseases increases by atleast ... 16. , The study ... The complete data will appear in the May 31st issue of ...
... Cleveland Clinic created a break through in ENT surgery by ... the recipient of the transplant is not able to speak ... in the motorcycle accident. He had been unable to speak ... motivational speeches to other patients and support groups. , ...
... In the era of fighting battle against cancer, researchers ... to execute the destiny. Radiation therapy is used to ... gene therapy makes cancer cells more susceptible to radiation ... kills cancer cells, it has unwanted side effects that ...
... (REM) sleep within a short time are more prone to ... Rochester Medical Center, doing a research on depression found that ... history of depression are twice as likely to get depressed ... of the five stages of sleep that we cycle through ...
... of children's tummies may offer a simple method of identifying ... at a later age.Among adults, fat around the waist is ... suggest that it is a better indicator of risk than ... ,A large waist is said to be associated with ...
... in Stroke: Journal of the American Heart Association, had ... much higher risk of heart attacks and developing heart ... the systolic blood pressure remaining between 120 and 139, ... mm Hg. Blood pressure hovering in any one of ...
Other Medicine News:Health News:Gene enchances radiation therapy - A novel approach to fight cancer 2Health News:Risk Of Heart Attack Increase From Pre-Hypertension 2
FlexStationII offers the highest level of flexibility in developing functional cellular assays and analyzing real time kinetic data....
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
... to end transcription services. Zodiac offers ... be either submitted over the phone ... call 24 hours a day, 7 ... be recorded on a digital handheld ...
... productivity in the lab with the OLA2500 ... pre- and post-analytical sorting requirements. As a ... and then sorts primary sample tubes to ... time, labor, and eliminate sample-handling errors. Post-analytical ...
Medicine Products: